Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 192
Rating:

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Prof Brian Baumann talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a comparative effectiveness study comparing proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer.

He explains that the hypotheses of the study was that proton therapy would reduce the side effects without reduction in the cancer control outcomes.

Prof Baumann reports that 1500 patients were studied across a range of cancers, with toxicity data gathered prospectively and then analysed

That analysis showed a 2/3 reduction in rates of grade 3 and higher toxicities in favour of proton therapy.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation